Q2 FY2026 EarningsQ2 FY26 results beat consensus across top and bottom-line metrics: revenue of $1,159M vs. $1,131M expected, and GAAP EPS of $1.35 vs. $1.12 expected. Performance was driven by robust demand for NovaSeq X consumables and the strategic acquisition of SomaLogic, despite significant macro headwinds in Greater China. Gross margin of 66.4% exceeded the 65.6% consensus, supported by operational efficiencies that offset rising freight and memory chip costs.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Illumina(ILMN) the Revenue is 1.159 B (+9.44%), Beat estimate;the EBIT is 260 M (+3.17%), Beat estimate;the EPS is 1.35 (-9.4%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
1.16B9.44%
1.13B6.76%
+0.03B2.68%
EBITExceed expectations
0.26B3.17%
0.25B1.53%
+0.01B4.70%
EPSExceed expectations
1.359.40%
1.120424.81%
+0.229615.41%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf